JWCA
ESPR

J.W. Cole Advisors’s Esperion Therapeutics ESPR Stock Holding History

J.W. Cole Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,415
Closed -$86.1K – 1609
2026
Q1 		$86.1K Hold
31,415
– – ﹤0.01% 764
2025
Q4 		$116K Sell
31,415
-2,485
-7% -$8.03K ﹤0.01% 1364
2025
Q3 		$89.8K Sell
33,900
-10,000
-23% -$19.3K ﹤0.01% 1496
2025
Q2 		$43.2K Hold
43,900
– – ﹤0.01% 1440
2025
Q1 		$63.2K Buy
43,900
+13,700
+45% +$25.2K ﹤0.01% 1220
2024
Q4 		$66.4K Buy
+30,200
New +$70.5K ﹤0.01% 940

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

J.W. Cole Advisors's ESPR Position: Q2 2026 in Review

J.W. Cole Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 31,415 shares — an estimated $86.1K sold.

J.W. Cole Advisors first reported a position in ESPR in Q4 2024 and held it in 6 quarters. The position peaked at $116K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • J.W. Cole Advisors reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J.W. Cole Advisors sold 31,415 Esperion Therapeutics shares in Q2 2026, an estimated $86.1K.
  • J.W. Cole Advisors first reported a position in Esperion Therapeutics in Q4 2024 and held it in 6 quarters.
  • J.W. Cole Advisors's Esperion Therapeutics position peaked at $116K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on J.W. Cole Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.